Interferon-beta1b in multiple sclerosis (Q36752915)

16 August 2017

1 reference

title

Interferon-beta1b in multiple sclerosis (English)

1 reference

16 August 2017

0 references

Mathias Buttmann

1 reference

16 August 2017

Peter Rieckmann

series ordinal

1 reference

16 August 2017

publication date

1 March 2007

1 reference

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

16 August 2017

published in

1 reference

16 August 2017

1 reference

16 August 2017

1 reference

16 August 2017

page(s)

227-239

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.3.227

16 August 2017

1 reference

The epidemiology of multiple sclerosis in Europe.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.3.227

Multiple sclerosis--the plaque and its pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.3.227

Benign course in multiple sclerosis: a review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.3.227

Secondary progressive multiple sclerosis: current knowledge and future challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.3.227

Primary progressive multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.3.227

Transitional progressive multiple sclerosis: a clinical and imaging study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.3.227

Two-year follow-up study of primary and transitional progressive multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.3.227

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.3.227

Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.3.227

Application of the new McDonald criteria to patients with clinically isolated syndromes suggestive of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.3.227

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.3.227

Improving MS patient care

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.3.227

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.3.227

Type I interferon [corrected] gene induction by the interferon regulatory factor family of transcription factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.3.227

Interferon signalling network in innate defence

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.3.227

Type 1 interferons and the virus-host relationship: a lesson in détente .

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.3.227

Intrathecal Interferon Reduces Exacerbations of Multiple Sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.3.227

A comparison of the mechanisms of action of interferon beta and glatiramer acetate in the treatment of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.3.227

The crystal structure of human interferon beta at 2.2-A resolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.3.227

Site-specific mutagenesis of the human fibroblast interferon gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.3.227

The human interferon alpha/beta receptor: characterization and molecular cloning

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.3.227

Type I interferons (alpha/beta) in immunity and autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.3.227

A comparison of the biologic activity of two recombinant IFN-beta preparations used in the treatment of relapsing-remitting multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.3.227

Neutralizing antibodies to interferon beta: implications for the management of multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.3.227

Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.3.227

Pharmacokinetics of recombinant human interferon-beta ser in healthy volunteers and its effect on serum neopterin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.3.227

Interferon (IFN)-beta treatment enhances CD95 and interleukin 10 expression but reduces interferon-gamma producing T cells in MS patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.3.227

Reduced expression of the inhibitor of apoptosis proteins in T cells from patients with multiple sclerosis following interferon-beta therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.3.227

Type I interferons keep activated T cells alive

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.3.227

Interferon-beta mediates stromal cell rescue of T cells from apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.3.227

21 January 2018

The B7 family revisited

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.3.227

Differential mechanisms of action of interferon-beta and glatiramer aetate in MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.3.227

Complex immunomodulatory effects of interferon-beta in multiple sclerosis include the upregulation of T helper 1-associated marker genes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.3.227

The impact of interferon-beta treatment on the blood-brain barrier

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.3.227

Glucocorticoid and type 1 interferon interactions at the blood-brain barrier: relevance for drug therapies for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.3.227

Interferon-beta stabilizes barrier characteristics of brain endothelial cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.3.227

Interferon-beta directly influences monocyte infiltration into the central nervous system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.3.227

Th1 and Th2 lymphocyte migration across the human BBB is specifically regulated by interferon beta and copolymer-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.3.227

Adhesion molecules and matrix metalloproteinases in Multiple Sclerosis: effects induced by Interferon-beta.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.3.227

Chemokine network in multiple sclerosis: role in pathogenesis and targeting for future treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.3.227

Interferon-beta induces transient systemic IP-10/CXCL10 chemokine release in patients with multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.3.227

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.3.227

Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.3.227

Hepatic reactions during treatment of multiple sclerosis with interferon-beta-1a: incidence and clinical significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.3.227

Psychiatric side effects of interferon-beta in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.3.227

Interferon-beta1b for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.3.227

The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. European Study Group on Interferon beta-1b in secondary progressive multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.3.227

Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.3.227

Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.3.227

Spotlight on Interferon-beta-1b in relapsing-remitting and secondary progressive multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.3.227

Interferon-beta 1b in the treatment of multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.3.227

An examination of the results of the EVIDENCE, INCOMIN, and phase III studies of interferon beta products in the treatment of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.3.227

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.3.227

Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.3.227

Interferon beta-1a in relapsing multiple sclerosis: four-year extension of the European IFNbeta-1a Dose-Comparison Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.3.227

Interferon beta-1b (betaseron/betaferon) is well tolerated at a dose of 500 microg: interferon dose escalation assessment of safety (IDEAS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.3.227

A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.3.227

Appearance and disappearance of neutralizing antibodies during interferon-beta therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.3.227

Biological markers of interferon-beta therapy: comparison among interferon-stimulated genes MxA, TRAIL and XAF-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.3.227

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.3.227

Immune response to immunotherapy: the role of neutralising antibodies to interferon beta in the treatment of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.3.227

Increases in soluble VCAM-1 correlate with a decrease in MRI lesions in multiple sclerosis treated with interferon beta-1b

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.3.227

Uncrossed cortico-muscular projections in humans are abundant to facial muscles of the upper and lower face, but may differ between sexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.3.227

Early onset multiple sclerosis: a longitudinal study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.3.227

Multiple sclerosis in childhood: clinical features of 149 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.3.227

Early onset MS under the age of 16: clinical and paraclinical features

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.3.227

Immunomodulatory treatment of early onset multiple sclerosis: results of an Italian Co-operative Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.3.227

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.3.227

Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.3.227

Progressive multifocal leukoencephalopathy in a patient treated with natalizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.3.227

Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.3.227

Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.3.227

Cladribine in treatment of chronic progressive multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.3.227

21 January 2018

Identifiers

DOI

10.1586/14737175.7.3.227

1 reference

16 August 2017

1 reference